Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment simplification to raltegravir-based triple therapy in virologically suppressed HIV patients with toxicity to current antiretroviral therapy
2009-014316-35Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of raltegravir, tenofovir, emtricitabine, abacavir and lamivudine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Policlinico Gemelli. Primary endpoints: Proportion of patients with virological failure within 48 weeks and Time to virological failure. Started Jul 2009; status: completed.
02
Drugs
raltegravirtenofoviremtricitabineabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-014316-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014316-35.